Dermal fillers are one of the most in-demand aesthetic procedures that can help women and men combat signs of aging and rejuvenate their faces without incisions, surgery, or downtime.
What’s more, hyaluronic acid fillers like Restylane are continuously advancing, especially with Restylane Lyft’s latest FDA approval.
Keep reading to learn all about Galderma’s most recent achievement.
Restylane Lyft: Galderma Announces Another FDA Approval
Galderma recently announced that their Restylane family of dermal fillers has gained a seventh FDA-approval. Restylane Lyft is now indicated for use with a small, blunt tip cannula for the purpose of cheek augmentation and correction of age-related midface contour irregularities.
This news is further evidence of Galderma’s desire to grow their aesthetic market with new delivery solutions for patients and providers.
Additionally, Restylane Lyft’s additional FDA-clearance increases treatment customization and makes dermal fillers a more inclusive option for a wide-range of patients.
What Is Restylane Lyft?
Restylane Lyft is a soft tissue dermal filler comprised of hyaluronic acid – a substance that’s naturally produced by the body and can provide instant volumizing and hydrating effects. This particular product is more robust, making it an excellent lifting and plumping agent for volume-depleted areas.
In fact, Restylane Lyft is the only hyaluronic acid filler with three FDA-approved indications, including the midface and cheeks, nasolabial folds, and back of the hands. It’s also the second Restylane product to receive clearance for cannula-use.
Restylane Lyft treatment benefits can last up to 12 months in the midface.
What Is a Cannula and How Is It Used With Dermal Fillers?
A cannula is a thin, flexible tube with openings on each side to deliver filler product. Many aesthetic experts prefer a cannula to a needle for certain facial areas. That’s because cannulas can help decrease damage to blood vessels and thereby reduce bruising, swelling, and downtime.
Study for Restylane Lyft’s Latest FDA approval
The safety and efficacy of administering Restylane Lyft with a cannula to the cheeks and midface was evaluated in a 16-week, US-based clinical study, with 60 male and female participants.
Results demonstrated a 98.3 percent patient response rate for the aesthetic improvement in the left and right midface, without any severe related adverse events.
If you are considering dermal fillers and want to learn more about Restylane Lyft’s latest FDA approval, please call our office today to schedule a comprehensive consultation with one of our highly-skilled and talented injectors.
